Ablin and colleagues [62] showed that after a single infusion of infliximab, (biological DMARD with anti-TNF action), in active seropositive RA patients, the level of EPCs increased significantly, by 33.4%, and EPCs adhesion and differentiation were also increased by 60% and 37.6%, respectively. This evidence concerns the gene TNF and rheumatoid arthritis.